Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Vascular · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%

IVIg vs acetylsalicylic acid (ASA)

Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD

Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
OR 0.6 [0.41, 0.87]
11 studies · 1437 participants
Moderate

IVIg vs acetylsalicylic acid (ASA)

Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD

It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
OR 0.57 [0.17, 1.89]
10 studies · 1376 participants
Very low

IVIg vs acetylsalicylic acid (ASA)

Acute coronary syndrome · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 202 participants
Low

IVIg vs acetylsalicylic acid (ASA)

Duration of fever · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 307 participants
Moderate

IVIg vs acetylsalicylic acid (ASA)

Need for extra treatment · people undergoing initial treatment for KD

Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in need for additional treatment (up to 30 or 60 days) compared with acetylsalicylic acid (ASA) (low certainty).

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
OR 0.27 [0.05, 1.57]
3 studies · 272 participants
Low

IVIg vs acetylsalicylic acid (ASA)

Length of hospital stay · people undergoing initial treatment for KD

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs acetylsalicylic acid (ASA)

Mortality (all‐cause) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low